Mixed
The prevalence of severe sarcopenia ranges from 2% to 9% globally, with higher rates observed in European studies using EWGSOP criteria compared to Asian/Oceanic studies using other classifications.
Severe sarcopenia, which combines low muscle mass with poor physical performance (like slow gait speed), affects 2-9% of the population depending on how it is measured. It is a stronger predictor of mortality than sarcopenia alone, so early identification using standardized performance tests is critical.
Finally, the prevalence of severe sarcopenia ranged from 2% to 9%.
Why this rating
Based on meta-analysis of 24 studies reporting severe sarcopenia, though fewer studies than general sarcopenia.
Source
Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta‐analysis
Fanny Petermann‐Rocha et al. · Journal of Cachexia Sarcopenia and Muscle · 2021
DOI 10.1002/jcsm.12783
Related findings · Mixed
- Bariatric surgery (VSG and RYGB) is the most effective and sustainable treatment for obesity, producing marked and sustained weight loss that non-surgical interventions cannot match.Strong
- Severely protein-deficient diets (2–3% energy) induce lean body mass loss and metabolic imbalance, whereas adequate protein intake (0.66 g/kg/d minimum) is a prerequisite for maintaining muscle, bone, and physiological function.Strong
- For patients with Class III obesity (BMI >39.9 kg/m2), metabolic bariatric surgery (MBS) is significantly more effective than any currently approved medication, with BilioPancreatic Diversion (BPD) showing the highest estimated weight loss.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →